Nivolumab is inhibitor of preprogrammed death-1 receptor: the role in malignant tumours treatment
Abstract
The creation of drugs - inhibitors of immune control points has significantly changed the standards for the treatment of common cancer. These drugs not only showed clinical activity against a wide range of solid tumors, but also have a favorable safety profile. A significant increase in overall survival compared to other antitumor approaches is the main advantage of immunotherapy. Nivolumab is an lgG4 antibody that blocks the interaction of the PD-1 receptor with its ligands, thereby negating the inhibition of the antitumor immune response. ln Russia, the drug is approved for the treatment of advanced melanoma, non-small cell lung cancer and kidney cancer.
About the Authors
M. D. Ter-Ovanesov
People’s Friendship University of Russia; Municipal Clinical Hospital No 40
Russian Federation
Russian Federation
M. Yu. Kukosh
People’s Friendship University of Russia; Municipal Clinical Hospital No 40
Russian Federation
Russian Federation
I. V. Pimenov
People’s Friendship University of Russia; Municipal Clinical Hospital No 40
Russian Federation
Russian Federation
D. L. Valkin
Municipal Clinical Hospital No 40
Russian Federation
Russian Federation
A. V. Levitsky
Municipal Clinical Hospital No 40
Russian Federation
Russian Federation
References
1. Rajan A., Kim C., Heery C. R., Guha U., Gulley J. L. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum. Vaccin. Immunother. 2016 Sep; 12 (9): 2219-31.
2. Регистрационное удостоверение. Ниволумаб (Опдиво). - URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7560c36a-e8e8-4092-8c46-e85f14a121e4&t= (дата обращения: 13.01.2017).
3. Krone B., Kolmel K. F., Grange J. M.: The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies. BMC Cancer 14: 595, 2014.
4. Parish C. R.: Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol. 81: 106-13, 2003.
5. Pardoll D.: Cancer and the Immune System: Basic Concepts and Targets for Intervention. Semin. Oncol. 42: 523-38, 2015.
6. Ribas A.: Releasing the Brakes on Cancer Immunotherapy. N. Engl. J. Med. 373: 1490-2, 2015.
7. Pardoll D. M.: The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12: 252-64, 2012
8. Kaprin A. D., Starinskij V. V., Petrova G. V. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2014 g. M. - 2015.
9. Davydov M. I., Polockij B. E. Sovremennye prin-cipy vybora lechebnoj taktiki i vozmozhnosti hirurgicheskogo lecheniya nemelkokletoch-nogo raka legkogo, sbornik Novoe v terapii raka legkogo. M. - 2003.
10. Горбунова В. А. Практические рекомендации RUSSCO: НМРЛ // www.rosoncoweb.ru.
11. Лактионов К. К., Саранцева К. А., Бредер В. В., Окружнова М. А., Перегудова М. В. Место иммуноонкологии в лечении немелкоклеточного рака легкого // Злокачественные опухоли. - 2016. № 3. - C. 17-24.
12. Brahmer J. R., Horn L., Jackman D., et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. Presented at: 2017 AACR Annual Meeting; April 1-5, 2017; Washington, DC. Abstract CT077.
13. Gettinger S. N., Horn L., Gandhi L., et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2015; 33 (18): 2004-12.
14. Brahmer J., Reckamp K. L., Baas P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 373 (2): 123-35.
15. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 373 (17): 1627-39.
16. Трапезникова М. Ф., Глыбин П. А., Морозов А. П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008; (4): 82-7.
17. David F. McDermott Long-term overall survival with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. 2016 ASCO Annual Meeting, abstract number: 4507.
18. Boccardo F., Rubagotti A., Canobbio L., et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. Tumori 1998; 84: 534-39.
19. Motzer R. J., Escudier B., McDermott D. F., et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015; 373: 1803-13.
20. Garbe C. 1, Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16 (1): 5-24. doi: 10.1634/theoncologist.2010-0190.
21. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015 Jan 1; 372 (1): 30-9.
22. Long G. V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 1; 386 (9992): 444-51.
23. Desvignes C., Abirached H., Templier C., Drumez E., Lepesant P., Desmedt E., Mortier L. BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response. Melanoma Res. 2017 Feb 24; Epub 2017 Feb 24.
24. Peggs K. S., Quezada S. A. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev. Anticancer Ther. 2010 Nov; 10 (11): 1697-701.
25. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimum-ab in Unresectable or Metastatic Melanoma. Schadendorf D et al. J. Clin. Oncol. 2015.
26. Grossmann K. F., Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinicalimplications. Ther. Adv. Med. Oncol. 2015 May; 7 (3): 181-91. doi: 10.1177/1758834015572284.
27. Weber J. S., D’Angelo S. P., Minor D., Hodi F. S., Gutzmer R. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr; 16 (4): 375-84.
28. Robert C. 1, Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J. C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015 Jan 22; 372 (4): 320-30.
29. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J. J., Cowey C. L., Lao C. D. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015 Jul 2; 373 (1): 23-34. doi: 10.1056/NEJ-Moa1504030. Epub 2015 May 31.
Review
For citations:
Ter-Ovanesov M.D., Kukosh M.Yu., Pimenov I.V., Valkin D.L., Levitsky A.V. Nivolumab is inhibitor of preprogrammed death-1 receptor: the role in malignant tumours treatment. Medical alphabet. 2017;1(16):23-28. (In Russ.)
Views:
296
Email this article 